Requip and Ampyra drug interactions - a phase IV clinical study of FDA data
Drug interactions are reported among people who take Requip and Ampyra. Common interactions include vomiting among females and drug ineffective among males.
The phase IV clinical study analyzes what interactions people who take Requip and Ampyra have. It is created by eHealthMe based on reports of 286 people who take Requip and Ampyra from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
286 people who take Requip and Ampyra together, and have interactions are studied.
What is Requip?
Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,097 Requip users for its effectiveness, alternative drugs and more.
What is Ampyra?
Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 75,229 Ampyra users for its effectiveness, alternative drugs and more.
Number of Requip and Ampyra reports submitted per year:
Requip and Ampyra drug interactions by gender *:
Requip and Ampyra drug interactions by age *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Requip and Ampyra?Personalize this study to your gender and age
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Alternative drugs to, pros and cons of the 2 drugs:
Common Requip and Ampyra interactions:
- Weakness: 35 reports
- Memory loss: 17 reports
Browse all drug interactions of Requip and Ampyra:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Requip side effects:
- Drug ineffective: 1,870 reports
- Fatigue (feeling of tiredness): 1,331 reports
- Drowsiness: 1,164 reports
- Dizziness: 1,134 reports
- Pain: 1,033 reports
Browse all side effects of Requip:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Ampyra side effects:
- Drug ineffective: 8,776 reports
- Weakness: 6,572 reports
- Fatigue (feeling of tiredness): 6,118 reports
- Urinary tract infection: 4,633 reports
Browse all side effects of Ampyra:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Requip interactions:
- Requip and Aspirin: 2,449 reports
- Requip and Sinemet: 1,967 reports
- Requip and Gabapentin: 1,668 reports
- Requip and Lasix: 1,564 reports
- Requip and Lyrica: 1,561 reports
- Requip and Lisinopril: 1,558 reports
- Requip and Synthroid: 1,505 reports
- Requip and Cymbalta: 1,494 reports
- Requip and Lipitor: 1,409 reports
- Requip and Neurontin: 1,258 reports
Browse all interactions between Requip and drugs from A to Z:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Ampyra interactions:
- Ampyra and Tecfidera: 12,461 reports
- Ampyra and Baclofen: 12,409 reports
- Ampyra and Vitamin d: 9,585 reports
- Ampyra and Gabapentin: 6,527 reports
- Ampyra and Tysabri: 5,776 reports
- Ampyra and Copaxone: 5,740 reports
- Ampyra and Avonex: 4,529 reports
- Ampyra and Gilenya: 3,954 reports
- Ampyra and Aspirin: 3,900 reports
- Ampyra and Aubagio: 3,719 reports
Browse all interactions between Ampyra and drugs from A to Z:a b c d e f g h i j k l m n o p q r s t u v w x y z
How the study uses the data?
The study uses data from the FDA. It is based on ropinirole hydrochloride and dalfampridine (the active ingredients of Requip and Ampyra, respectively), and Requip and Ampyra (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Requip and Ampyra.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Enoxaparin Sodium and Urticaria Aggravated - 16 seconds ago
- Gabapentin and Green Coffee Bean drug interaction - 25 seconds ago
- Protonix and Pulmonary Haematoma - 35 seconds ago
- Melatonin and Lymphoedema - 50 seconds ago
- Linzess and Menopause - 51 seconds ago
- Clopidogrel Bisulfate and Pituitary Enlargement - 51 seconds ago
- Plan B and Ibu drug interaction - 52 seconds ago
- Hair Loss and Attention Deficit Hyperactivity Disorder - a minute ago
- Hair Loss and Attention Deficit/Hyperactivity Disorder - a minute ago
- Avapro and Throat Irritation - a minute ago